Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES, CA / ACCESSWIRE / August 7, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ: WBA ) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 12, 2023 and June 26, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

Investors Are Invited To Take The Lead In The Walgreens Boots Alliance Inc Securities Fraud Case With The Schall Law Firm

Walgreens Boots Alliance may sell its entire stake in doctor-staffed clinic operator VillageMD, which has already cost the drugstore giant billions of dollars.

Walgreens May Sell Off Entire Stake In Clinic Operator VillageMD

NEW YORK, NY / ACCESSWIRE / August 7, 2024 / If you suffered a loss on your Walgreens Boots Alliance, Inc. (NASDAQ:WBA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/walgreens-boots-alliance-inc-lawsuit-submission-form?prid=94455&wire=1 or contact Joseph E. Levi, Esq.

Class Action Filed Against Walgreens Boots Alliance, Inc. (WBA) - September 10, 2024 Deadline to Join – Contact Levi & Korsinsky

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Walgreens Boots Alliance, Inc. (NASDAQ: WBA).

The Gross Law Firm Reminds Walgreens Boots Alliance, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 10, 2024 – WBA

SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Walgreens Boots Alliance, Inc. (NASDAQ: WBA) securities between October 12, 2023 and June 26, 2024, all dates inclusive (the “Class Period”), have until September 10, 2024 to seek appointment as lead plaintiff of the Walgreens class action lawsuit. Captioned Bhaila v. Walgreens Boots Alliance, Inc., No. 24-cv-05907 (N.D. Ill.), the Walgreens class action lawsuit charges Walgreens as well as certain of Walgreens' top executives with violations of the Securities Exchange Act of 1934.

WBA INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Walgreens Boots Alliance, Inc. Investors with Substantial Losses Have Opportunity to Lead Case

LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ: WBA ) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 12, 2023 and June 26, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

WBA Investors Can Lead The Walgreens Boots Alliance Inc Securities Fraud Lawsuit With The Schall Law Firm

NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Walgreens Boots Alliance, Inc. (NASDAQ: WBA) between October 12, 2023 and June 26, 2024, both dates inclusive (the “Class Period”), of the important September 10, 2024 lead plaintiff deadline.

ROSEN, LEADING INVESTOR COUNSEL, Encourages Walgreens Boots Alliance, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – WBA

DEERFIELD, Ill. & SAN FRANCISCO--(BUSINESS WIRE)--Walgreens, the leading integrated independent retail pharmacy and healthcare provider, today announced a new collaboration with Instacart, the leading grocery technology company in North America, to offer online SNAP/EBT payment acceptance at more than 7,500 Walgreens stores nationwide, including over 100 Duane Reade locations in New York. Customers can now purchase thousands of SNAP-eligible products for same-day delivery via Instacart. Through.

Walgreens & Instacart Collaborate to Accept SNAP/EBT Online Nationwide

Etsy

NIKE

The S&P 500 has been a common choice for passive investors. It has delivered steady returns over the years, especially for investors who withstood market corrections and continued to make regular investments.

Get Your Money Out of These 3 S&P 500 Stocks by 2025

NEW YORK , Aug. 5, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Walgreens Boots Alliance, Inc. (NASDAQ: WBA). Shareholders who purchased shares of WBA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Walgreens Boots Alliance, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before September 10, 2024 to Discuss Your Rights - WBA

CVS Health

Walgreens is citing macro issues, like a worsening consumer environment and pressure on pharmacy margins, while grappling with its own set of issues.

Why pharmacy chains like Walgreens and CVS are shuttering locations

As my worst investment in over 20 years, Walgreens Boots Alliance, Inc. stock served me a painful lesson about turnaround. Turnaround requires fundamentally sound business economics and plenty of financial resources. I misjudged Walgreens Boots Alliance's business economics badly.

Walgreens: A Painful Turnaround Lesson

NEW YORK, Aug. 02, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Walgreens Boots Alliance, Inc. (NASDAQ: WBA) between October 12, 2023 and June 26, 2024, both dates inclusive (the “Class Period”), of the important September 10, 2024 lead plaintiff deadline.

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Walgreens Boots Alliance, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – WBA

Cencora Inc

Struggling drug-store chain Walgreens Boots Alliance Inc. has sold off shares of drug distributor Cencora Inc., handing the retailer some $1.1 billion in proceeds as it tries to carry out a turnaround plan and pay down debt.

Walgreens continues to shed stake in Cencora as it looks to bolster turnaround

Walgreens Boots Alliance has sold more shares of drug distributor Cencora for proceeds of about $1.1 billion, which will be used “primarily for debt paydown and general corporate purposes.”

Walgreens Sells Another Stake In Distributor Cencora For $1.1 Billion

Walgreens Boots Alliance said on Thursday it has sold shares in drug distributor Cencora for proceeds of about $1.1 billion.

Walgreens further reduces stake in Cencora

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that it has sold all of its remaining unencumbered shares of Cencora, Inc. (NYSE: COR) common stock pursuant to Rule 144 for proceeds of $818 million and, subject to the completion of the Rule 144 sale, a concurrent share repurchase by Cencora in the amount of $250 million. Walgreens Boots Alliance's ownership of Cencora's common stock has decreased from approximately 12 percent to approximately 10 pe.

Walgreens Boots Alliance Sells Shares of Cencora for Approximately $1.1 Billion of Proceeds

NEW YORK, NY / ACCESSWIRE / August 1, 2024 / If you suffered a loss on your Walgreens Boots Alliance, Inc. (NASDAQ:WBA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/walgreens-boots-alliance-inc-lawsuit-submission-form?prid=93391&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that Lost mMoney on Walgreens Boots Alliance, Inc.(WBA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

PayPal

Warner Bros Discovery Inc

Understanding the fundamentals behind top stock opportunities is critical to making potent investments. Here, the focus is on three solid stocks.

3 Unbelievable Opportunities on the Verge of a Surge

Zacks.com users have recently been watching Walgreens (WBA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Walgreens Boots Alliance, Inc. (WBA) is Attracting Investor Attention: Here is What You Should Know

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens is now offering flu shots for anyone aged 3 years and up at stores nationwide ahead of respiratory illness season. Individuals and families can visit the pharmacy or schedule an appointment through the Walgreens app, by visiting Walgreens.com/ScheduleVaccine or by calling 1-800-WALGREENS. Walgreens trusted pharmacy teams are working to keep communities protected this upcoming respiratory season by helping to ensure everyone has convenient and timely o.

Walgreens Flu Shot Appointments Now Available Nationwide for Everyone Aged 3 and Up

SAN DIEGO, CA / ACCESSWIRE / August 1, 2024 / Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Walgreens Boots Alliance, Inc. (NASDAQ:WBA) securities between October 12, 2023 and June 26, 2024, inclusive (the "Class Period"), have until September 10, 2024 to seek appointment as lead plaintiff of the Walgreens class action lawsuit. Captioned Bhaila v.

WBA INVESTOR DEADLINE: Walgreens Boots Alliance, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Walgreens Boots Alliance, Inc. (NASDAQ: WBA).

Investors in Walgreens Boots Alliance, Inc. Should Contact The Gross Law Firm Before September 10, 2024 to Discuss Your Rights – WBA

LOS ANGELES, CA / ACCESSWIRE / July 30, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ: WBA ) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 12, 2023 and June 26, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

WBA Investors Can Head The Walgreens Boots Alliance Inc Securities Fraud Lawsuit With The Schall Law Firm

Annaly Capital

Dividend stocks have crushed non-payers in the return column over the last 50 years. Eight of Wall Street's smartest (and richest) money managers sent shares of artificial intelligence (AI) juggernaut Nvidia to the chopping block in the March-ended quarter.

News for Walgreens Stock (WBA)